We assessed nationwide practice patterns and examined factors associated with patients undergoing completion ALND and subsequent radiation field design.
Another area of EF4 damage was observed east of Enterprise as a new home undergoing completion was leveled, with the debris swept off the foundation.
*While this manuscript was undergoing completion, we learned that the X-ray structure of PLP synthase from S. cerevisiae with PLP and G3P bound was accepted for publication [42].
Fewer than half of women undergoing completion axillary lymph node dissection (ALND) for breast cancer will have non-sentinel node (NSLN) metastasis.
Those patients would not undergo completion node dissection and hence would be at risk of failure in nonsentinel nodes, and these cases would be considered false-negative results.
In a study involving 335 patients with a median follow-up of 33 months, 15 patients (4.5%) who had negative SLNB and who did not undergo completion axillary dissection developed a cancer recurrence.
Considering the risk of potential bias due to low sentinel node tumor burden in our dataset, we applied both our model and the MSKCC Nomogram to an independent dataset of 77 SLN positive patients who underwent completion ALND.
We excluded screenees undergoing completion CTC after incomplete colonoscopy since many of these will be due to an obstructing tumour (and hence would inflate the CTC cancer detection rate via inclusion bias).
William Osler In this issue of Annals of Surgical Oncology, Kingham et al. from Memorial Sloan-Kettering Cancer Center present their single-institution retrospective experience of melanoma patients who did not undergo completion lymph node dissection (CLND) for a tumor-positive sentinel lymph node (SLN). 1 Of 313 patients who had a tumor-positive SLN, 271 underwent CLND and 42 did not.
It is comprised of 77 consecutively identified sentinel node positive patients with invasive breast cancer who underwent completion ALND and had complete pathologic information on tumor type, tumor size, tumor grade, hormone receptor status, HER2/ neu status, angiolymphatic invasion status, number of nodes removed, and size of sentinel node metastases.
